CF

We are delighted to announce CF as a finalist in the 2024 LaingBuisson Awards, shortlisted for ‘Consultancy of the Year’! The prestigious awards ceremony recognises organisations shaping the health and social care landscape and we are proud to be nominated amongst industry leaders in the health sector. Congratulations to the entire CF team, and good luck to all other finalists ⭐ Find out more here: https://lnkd.in/eH_dCtq2 #LaingBuissonAwards2024 #LBAwards24

#WorldAlzheimersMonth is a crucial time for raising awareness and challenging the stigma surrounding Alzheimer’s disease and dementia. Throughout September, we will be showcasing the work we've undertaken to deliver better outcomes for people living with dementia, their families, and carers. Ben Richardson reflects on what more needs to be done to drive meaningful change ⤵️ #WorldAlzMonth #TimeToActOnDementia #TimeToActOnAlzheimers

In a rapidly evolving health sector, it is vital that leaders and their teams are equipped with cutting-edge knowledge and strategic approaches to operate effectively. For over a decade, we have worked within and across the NHS, as clinicians, executive directors, service managers and programme directors offering flexible and engaging training and development. We support organisations to grow their talent - empowering them to navigate the toughest of challenges in health care and life sciences. From helping clients understand what it takes to do a major service change in health systems, to supporting life sciences and pharma clients navigate NHS policy frameworks, we set teams up for success. 🚀 Find out more about CF training and development here, and get in touch today 🔗 https://lnkd.in/eU8hGy7E #CF #TrainingandDevelopment #NHS #LifeSciences

Back in May CF published a landmark study with the Alzheimer's Society setting out the staggering economic and healthcare cost of dementia. Since the report (based on a linked, record-level healthcare dataset of over 26,000 individuals) was published Ben Richardson and I have been engaging with investors from across the European health and care market to understand its implications, both today and for the years leading up to 2040. Writing for LaingBuisson's CareMarkets we have set out both the scale of the challenge facing the UK and the range of opportunities this presents for innovators, investors and service providers. We have identified five key ways in which investors can engage with the increasing dementia burden and help the UK to recalibrate services and funding structures to respond to the dementia challenge: 1️⃣ Expedite Diagnostic Pathways: Early diagnosis is key to improving outcomes for dementia patients. Increasing diagnostic capacity and awareness among clinicians and patients is crucial to realising benefits of DMTs. 2️⃣ Address Bed Capacity: The UK faces a staggering shortfall of +100,000 care beds between now and 2040. The need for long-term capital to build and operate fit for purpose facilities is significant. 3️⃣ Enable New Care & Funding Models: Recalibrating care pathways will only be possible with new funding and commissioning arrangements, with investors with access to long-term sustainable capital crucial to achieving lasting structural change. 4️⃣ Support Digital Innovation: Providing technology to transform patient pathways from diagnosis through to treatment is both an opportunity and a challenge. Investors with vision and patience will be vital for unlocking innovation. 5️⃣ Expand Data Environment: Transforming data infrastructure is fundamental to both realising the benefits of technology and managing the burden of dementia. The UK requires long-term investment into data environments such as the FDP. To read the full analysis please check out our article here. Thanks to Deven Pamben and Tim Read for featuring our work. #dementia #alzheimers #healthcare  https://lnkd.in/gkpWpQ8d

As the leading cause of death in the UK, and its prevalence growing at a rapid rate, dementia is becoming one of the leading health crises of our time: - In 2024 there are currently an estimated 1 million people living with dementia, a number expected to rise to 1.4 million by 2040 - The financial burden is significant, with costs projected to reach £42 billion in 2024 and escalate to £90 billion by 2040 A combination of inconsistencies in care quality, underfunding, an over-reliance on unpaid care, regional challenges and increasing costs are driving the need to reimagine the dementia landscape. And with demand at an all-time high for our National Health Service, private capital needs to play a pivotal role in driving change. Drawing on insights from our landmark report with the Alzheimer's Society earlier this year, Ben Richardson and Vernon Baxter have identified five key areas for investors, as published in LaingBuisson’s CareMarkets: https://lnkd.in/gdUempte Discover more here 🔗 https://lnkd.in/giVWJuDj

Excited to share that as part of CF's growth journey, we are recruiting for a Director to help shape the future of public sector healthcare. Ideal candidates will have extensive experience in healthcare consulting, a proven track record of impactful delivery, and the ability to mentor and develop high-performing teams. If you're an experienced leader passionate about making a real impact in the health sector, we'd love to hear from you! #hiring # healthcare #cfcareers

Addressing access and adoption of medicines in the UK is fundamental to ensure patients receive the best possible care. 💊 The country's ambition to become a Life Sciences powerhouse is supported by a renowned science and regulatory environment, and a unique health system and data access. So why has investment from global pharmaceutical companies been declining in recent years? Now is the time to take decisive action to address access and adoption. Read more in our latest article here 🔗 https://lnkd.in/ewmimBhS #Pharma #MarketAccess #Healthcare NHS The Association of the British Pharmaceutical Industry (ABPI) Department of Health and Social Care

⭐ New CF opportunity ⭐ We are hiring a Personal Assistant to join our growing team. This role will be an integral part of CF’s day-to-day operations; supporting Partners to coordinate their corporate, client and business development requirements. Are you highly adaptable, with exceptional organisational and communication skills, and looking for an opportunity to make a real impact? Find out more and apply here: https://lnkd.in/gWvcsppz View all of our current vacancies here: https://lnkd.in/eQXPzcHF

The FDA has released guidance as part of its Real World Evidence Program to enhance regulatory decision-making on the effectiveness and safety of drug and biological products. It offers key considerations for sponsors and stakeholders when proposing to use electronic health records (EHRs) or medical claims data in clinical studies. Our latest snapshot reveals highlights from the guidance ⬇️ 1. Study Preparation 📝 - Decide your essential elements of study design in advance, submit protocols and statistical analysis plans, and maintain engagement with the FDA. 2. Data Sources 📚 - Check the relevance and reliability of data sources, clearly identify the study population, factors you are studying, outcomes, and confounders/effect modifiers. 3. Data Quality 📈 - Maintain high data quality throughout the data lifecycle, from collection to final dataset transformation. 4. Study Design 🧰 - Clearly define time periods and outline methods for patient inclusion/exclusion criteria.   5. Validation ✅ - Ensure accurate measurement of your study's variables. For more detailed information, refer to the FDA's guidance: https://lnkd.in/geANjjW7 See our snapshot here 🔗 https://lnkd.in/eiac7AdP #FDA #RealWorldEvidence #Pharma #Biotech #ClinicalStudies #EHR #RegulatoryScience #DrugSafety